#rare disease drugs

1 story

#astria therapeutics #bcrx #biocryst #business #finance #hereditary angioedema #nasdaq #navenibart #orladeyo

BioCryst Turns First Profit
BioCryst becomes profitable with Orladeyo and plans rare disease acquisitions.
Yahoo Finance · 1m